Safety and efficacy of docetaxel, estramustine phosphate and hydrocortisone in hormone-refractory prostate cancer patients

International Journal of Urology

Volumn 17, Issue 7, 2010, Pages 629-634

  Nakagami, Yoshihiro ^a   Ohori, Makoto ^a   Sakamoto, Noboru ^a   Koga, Shoji ^b   Hamada, Riu ^a   Hatano, Tadashi ^a   Tachibana, Masaaki ^a  

^a TOKYO MEDICAL UNIVERSITY   (Japan)

^b 2 24 18 Higashikoiwa   (Japan)

Author keywords

chemotherapy; docetaxel; estramustine phosphate; hormone refractory prostate cancer

Indexed keywords

ALKALINE PHOSPHATASE; DEXAMETHASONE; DOCETAXEL; ESTRADIOL; ESTRAMUSTINE; ESTRAMUSTINE PHOSPHATE; FOSFESTROL; HEMOGLOBIN; HYDROCORTISONE; MITOXANTRONE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; UFT;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER SURVIVAL; DIGESTIVE SYSTEM PERFORATION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; EDEMA; EVENING DOSAGE; FATIGUE; HEART INFARCTION; HEART LEFT VENTRICLE FAILURE; HORMONE REFRACTORY PROSTATE CANCER; HUMAN; INTESTINAL BLEEDING; LIVER DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MORNING DOSAGE; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OVERALL SURVIVAL; PRIORITY JOURNAL; PROSTATE CANCER; RETROSPECTIVE STUDY; THROMBOCYTOPENIA; TREATMENT OUTCOME;

ADENOCARCINOMA; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DRUG THERAPY, COMBINATION; ESTRAMUSTINE; HUMANS; HYDROCORTISONE; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; TAXOIDS;

EID: 77953840258     PISSN: 09198172     EISSN: 14422042     Source Type: Journal    
DOI: 10.1111/j.1442-2042.2010.02544.x     Document Type: Article

References (15)

1. Matsuda T, Marugame T, Kamo K et al. Cancer Statistics in Japan 2008. Center for Cancer Control and Information Services, National Cancer Center
2. Ohno Y. Prediction of Cancer Incidence in Japan. Cancer Statistics-2004. Shinohara Shuppan
3. Kaisary AV, Tyrrell CJ, Peeling WB et al. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma. Br. J. Urol. 1991 67: 502 508.
4. Petrylak DP, Macarthur RB, O'Connor J et al. Phase I trial of docetaxel with estramustine in androgen-independent prostate cancer. J. Clin. Oncol. 1999 17: 958 967.
5. Kreis W, Budman DR, Fetten J, Gonzales AL, Barile B, Vinciguerra V. Phase I trial of the combination of daily estramustine phosphate and intermittent docetaxel in patients with metastatic hormone refractory prostate carcinoma. Ann. Oncol. 1999 10: 33 8.
6. Berthold DR, Pond GR, Soban F, de Wit R, Eisenberger M, Tannock IF. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study. J. Clin. Oncol. 2008 26: 242 245.
7. Savarese DM, Halabi S, Hars V et al. Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. J. Clin. Oncol. 2001 19: 2509 2516.
8. Bubley GJ, Carducci M, Dahut W et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: Recommendations from the prostate-specific antigen working group. J. Clin. Oncol. 1999 17: 3461 3467.
9. Scher HI, Halabi S, Tannock I et al. Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: Recommendations of the prostate cancer clinical trials working group. J. Clin. Oncol. 2008 26: 1148 1159.
10. Tannock IF, de Wit R, Berry WR et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N. Engl. J. Med. 2004 351: 1502 1512.
11. Petrylak DP, Tangen CM, Hussain MHA et al. Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer. N. Engl. J. Med. 2004 351: 1513 1520.
12. Suzuki H, Okihara K, Miyake H et al. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade. J. Urol. 2008 180: 921 927.
13. Fizazi K, Le Maitre A, Hudes G et al. Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data. Lancet Oncol. 2007 8: 994 1000.
14. Machiels JP, Mazzeo F, Clausse M et al. Prospective randomized study comparing docetaxel, estramustine, and prednisone with docetaxel and prednisone in metastatic hormone-refractory prostate cancer. J. Clin. Oncol. 2008 26: 5261 5268.
15. Armstrong AJ, Garrett-Mayer ES, Yang YCO, de Wit R, Tannock IF, Eisenberger M. A contemporary prognostic nomogram for men with hormone-refractory metastatic prostate cancer: a TAX327 study analysis. Clin. Cancer Res. 2007 13: 6396 6403.